Today we reported our first quarter 2024 financial results. Read the full announcement here bit.ly/4dr74Q5

Today we’re sharing new preclinical data from our novel EGFR sparing, CNS-penetrant ErbB2 inhibitor at the #AACR24 Annual Meeting. Read our press release for more bit.ly/4aNJZFm and see the poster here bit.ly/3JaaSrd.

We’re looking forward to the Leerink Biopharma Conference. Join us tomorrow for a fireside chat with our President and CEO, Andrew Robbins. Register here: investors.cogentbio.com/events
#AdvSM #nonAdvSM #GIST #raredisease

Cogent is proud to support Rare Disease Day to raise awareness of the 300 million+ people living with a rare disease. We are focused on helping to advance therapies for rare diseases such as Systemic Mastocytosis & Gastrointestinal Stromal Tumors #RareDiseaseDay #shareyourcolours

Today we reported our Fourth Quarter and Full Year 2023 financial results and highlighted our recent company progress. Learn more here: bit.ly/3SV1U5l

We’re at #AAAAI24 this weekend presenting data from SUMMIT Part 1b with bezuclastinib in #NonAdvSM . Tune in to our webcast today, Friday, February 23 at 8:00am ET, to hear the Cogent team and Dr. Frank Siebenhaar review the data. Register and listen here edge.media-server.com/mmc/p/ypffzbp8

Join us at the upcoming American Academy of Allergy, Asthma & Immunology #AAAAI24 Annual Meeting in Washington, DC, Feb 23-26. Make sure to stop by Booth 811 to meet our team and learn more about Cogent!

Today we announced our milestones for 2024. Join us at 4:30pm PT/7:30pm ET for our #JPM24 presentation and hear our CEO, Andrew Robbins, discuss these milestones and our 2023 achievements. Read more bit.ly/48Djh10 and listen here investors.cogentbio.com/events

2023 marked a year of great progress at Cogent. We look forward to sharing more at #JPM24 tomorrow, Jan 9. A webcast will be available during & following the event.
investors.cogentbio.com/events

There is still time to register! Join Cogent Biosciences in collaboration w/The Life Raft Group, Wed. Dec. 13 7:00pm ET for a free educational webinar for the GIST community providing info on our Peak Clinical Trial (NCT05208047).

Register now using the link here: events.bizzabo.com/GIST_ClinicalT…

The targeted therapy bezuclastinib reduces disease burden and improves symptoms for patients with system mastocytosis, according to findings presented by our Dr. Prithviraj Bose at #ASH23 (Abstract 77).
Learn about it here: bit.ly/487o6zk Prithviraj Bose ASH…

Today we announced positive initial data from our Phase 2 SUMMIT trial with bezuclastinib in #nonAdvSM at #ASH23 . Read the update bit.ly/46QJGHe and tune into our webcast Monday morning at 8am ET/5am PT investors.cogentbio.com/events.

The Cogent team is headed to San Diego for #ASH23 . Come see us at Booth #2704 to learn more about our programs and our commitment to improving the lives of people living with #AdvSM #nonAdvSM #raredisease .

Today we announced new preclinical data highlighting potential best-in-class potency & selectivity of our ErbB2 program & our 3rd discovery program, a novel PI3Kα inhibitor at #SABCSSanAntonio . Read the PR bit.ly/47MdqXc & find the posters here bit.ly/3Rxvspl

In collaboration with The Life Raft Group, Cogent Biosciences will be hosting a webinar for the GIST Patient & Caregiver Community. Dr. Jonathan Trent will be presenting an overview of our Peak Clinical Trial (NCT05208047).

Register now using the link here: events.bizzabo.com/GIST_ClinicalT…

Tune in this afternoon at 2:30pm ET to listen to our Fireside Chat at the 35th Annual Piper Sandler Healthcare conference. Details are on our website here. investors.cogentbio.com/events

To recognize #NationalFamilyCaregiversMonth and those who support loved ones living with cancer including #GIST , Cogent joined American Cancer Society Boston Hope Lodge to serve dinner & assemble 96 care packages for residents & caregivers, we were humbled by their resilience & strength.

Tune in on Wednesday, Nov 15 at 12:00pm GMT/7:00am ET to listen to our webcast at the #JefferiesHealthcare London conference. Register and join here investors.cogenbio.com/events.

Today Dr. Neeta Somaiah from the MD Anderson Cancer Center discussed updated data from our Phase 3 #PEAK study in #GIST during a Trial In Progress (TiP) presentation at #CTOS2023 . Access the slides here. bit.ly/3SoOZu7

Today we reported our 3Q 2023 financial results and recent business highlights, including our upcoming #nonAdvSM SUMMIT oral presentation and our #AdvSM APEX poster at the upcoming #ASH23 annual meeting. Read the press release for more. bit.ly/46XPRKw